A Phase I Clinical Trial to Evaluate the Safety and Tolerability of TQB3823 Tablets in Subjects With Advanced Malignancies
Latest Information Update: 26 Jul 2023
At a glance
- Drugs TQB 3823 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 20 Jul 2023 Planned End Date changed from 1 Oct 2022 to 1 Oct 2025.
- 20 Jul 2023 Planned primary completion date changed from 1 Mar 2022 to 1 Feb 2025.
- 20 Jul 2023 Status changed from recruiting to active, no longer recruiting.